138 related articles for article (PubMed ID: 6297529)
1. High dose cyclophosphamide treatment of human oat cell xenografts in immune deprived mice.
Evans BD; Smith IE; Millar JL
Br J Cancer; 1983 Feb; 47(2):215-9. PubMed ID: 6297529
[TBL] [Abstract][Full Text] [Related]
2. Prevention of acute deaths in mice after very high dose cyclophosphamide by divided dose schedule.
Evans BD; Smith IE; Clutterbuck RD; Millar JL
Br J Cancer; 1984 Jan; 49(1):43-7. PubMed ID: 6318789
[TBL] [Abstract][Full Text] [Related]
3. Experimental combination and single-agent chemotherapy in human lung-tumour xenografts.
Shorthouse AJ; Jones JM; Steel GG; Peckham MJ
Br J Cancer; 1982 Jul; 46(1):35-44. PubMed ID: 6285948
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic response of bronchial carcinoma xenografts: a direct patient-xenograft comparison.
Shorthouse AJ; Peckham MJ; Smyth JF; Steel GG
Br J Cancer Suppl; 1980 Apr; 4():142-5. PubMed ID: 6252930
[TBL] [Abstract][Full Text] [Related]
5. Preclinical phase II study of ifosfamide in human tumour xenografts in vivo.
Berger DP; Fiebig HH; Winterhalter BR; Wallbrecher E; Henss H
Cancer Chemother Pharmacol; 1990; 26 Suppl():S7-11. PubMed ID: 2347054
[TBL] [Abstract][Full Text] [Related]
6. The human tumour xenograft--a valid model in experimental chemotherapy?
Shorthouse AJ; Smyth JF; Steel GG; Ellison M; Mills J; Peckham MJ
Br J Surg; 1980 Oct; 67(10):715-22. PubMed ID: 6253000
[TBL] [Abstract][Full Text] [Related]
7. Chemoprotective effects of recombinant human IL-1 alpha in cyclophosphamide-treated normal and tumor-bearing mice. Protection from acute toxicity, hematologic effects, development of late mortality, and enhanced therapeutic efficacy.
Futami H; Jansen R; MacPhee MJ; Keller J; McCormick K; Longo DL; Oppenheim JJ; Ruscetti FW; Wiltrout RH
J Immunol; 1990 Dec; 145(12):4121-30. PubMed ID: 2258610
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic response of human lung tumour xenografts to cyclophosphamide.
Mattern J; Jaeger S; Wayss K; Volm M
Anticancer Res; 1982; 2(6):355-8. PubMed ID: 7168553
[TBL] [Abstract][Full Text] [Related]
9. Failure to relate the anti-tumour action of cyclophosphamide with the immunogenicity of two murine fibrosarcomas.
Evans R
Int J Cancer; 1978 May; 21(5):611-6. PubMed ID: 659026
[TBL] [Abstract][Full Text] [Related]
10. Resistance to alkylating agents and tumour differentiation in xenografts of small cell lung cancer.
Berman R; Gusterson B; Steel GG
Br J Cancer; 1985 May; 51(5):653-8. PubMed ID: 2581600
[TBL] [Abstract][Full Text] [Related]
11. Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide.
Mokyr MB; Dray S
Cancer Res; 1983 Jul; 43(7):3112-9. PubMed ID: 6850619
[TBL] [Abstract][Full Text] [Related]
12. Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
Borden EC; Sidky YA; Hatcher JF; Bryan GT
Cancer Res; 1988 May; 48(9):2329-34. PubMed ID: 3356000
[TBL] [Abstract][Full Text] [Related]
13. Cyclophosphamide-induced lung damage in mice: protection by a small preliminary dose.
Collis CH; Wilson CM; Jones JM
Br J Cancer; 1980 Jun; 41(6):901-7. PubMed ID: 7426315
[TBL] [Abstract][Full Text] [Related]
14. Enhanced cell killing in lewis lung carcinoma and a human pancreatic-carcinoma xenograft by the combination of cytotoxic drugs and misonidazole.
Stephens TC; Courtenay VD; Mills J; Peacock JH; Rose CM; Spooner D
Br J Cancer; 1981 Apr; 43(4):451-7. PubMed ID: 7236488
[TBL] [Abstract][Full Text] [Related]
15. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K; O'Byrne K; Cai RZ
Br J Cancer; 1994 Nov; 70(5):886-92. PubMed ID: 7947094
[TBL] [Abstract][Full Text] [Related]
16. Effect of tumor size on S-2-(3-aminopropylamino)ethylphosphorothioic acid and misonidazole alteration of tumor response to cyclophosphamide.
Milas L; Ito H; Hunter N
Cancer Res; 1983 Jul; 43(7):3050-6. PubMed ID: 6303574
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity to cytotoxic agents of the EMT6 tumour in vivo: tumour volume versus in vitro plating. 1. Cyclophosphamide.
Twentyman PR
Br J Cancer; 1977 Feb; 35(2):208-17. PubMed ID: 836758
[TBL] [Abstract][Full Text] [Related]
18. Human tumour xenografts growing in immunodeficient mice: a useful model for assessing chemotherapeutic agents in bronchial carcinoma.
Fergusson RJ; Carmichael J; Smyth JF
Thorax; 1986 May; 41(5):376-80. PubMed ID: 3750245
[TBL] [Abstract][Full Text] [Related]
19. Lewis lung carcinoma in mice as an experimental therapy model. II. The effect of BCNU, cyclophosphamide and/or surgery treatment on early and advanced tumor in mice.
Budzyński W
Arch Immunol Ther Exp (Warsz); 1982; 30(5-6):373-7. PubMed ID: 7184488
[TBL] [Abstract][Full Text] [Related]
20. Sensitivity of human non-small cell lung cancer xenografts to cyclophosphamide and cisplatin.
Mattern J; Wayss K; Volm M
In Vivo; 1987; 1(1):23-6. PubMed ID: 2856516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
